Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

rability profiles in heart patients.

The company will use the results from this study to inform dose

selection for a larger Phase IIb trial planned to commence early next

year. The company is at the same time advancing the reformulation of

DG031, which also targets the leukotriene pathway for the prevention of

heart attack. The company has completed an accelerated 3-month

stability study with its lead reformulation and expects to complete

pharmacokinetic analysis of its bioequivalence study before the end of

this year.

-- DG041 for arterial thrombosis. In the past quarter deCODE has

successfully completed additional clinical studies with DG041, its

novel, first in class antagonist of the EP3 receptor for prostaglandins

E2. deCODE is developing DG041 as a next-generation oral anti-platelet

therapy -- a mechanism specific means of preventing arterial thrombosis

without increasing bleeding time. Clinical studies completed early this

summer demonstrated that in a concentration-dependent manner DG041

dramatically inhibits platelet activation mediated through vasodilator-

stimulated phosphoprotein (VASP) as well as platelet aggregation.

Moreover, the desired effect on VASP -- a biomarker useful for gauging

platelet activation -- appears to be achievable at doses lower than

previously anticipated. The company has built on those results in the

past quarter with the completion of two drug-drug interaction studies

that showed DG041 to have a very satisfactory DDI profile. Moreover, in

a double-blind, placebo-controlled clinical study, DG041 was shown to

have the desired effect on VASP, and in a significant and

concentration-dependent manner, irrespective of whether subjects were

also receiving aspirin. This supports DG041's development as a compoun
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Knowledgent , the data and analytics ... potential of big data analytics in the life sciences ... help life sciences and healthcare organizations understand the ways ... business insights. , The life sciences and healthcare industries ... patient profiling, compliance and regulatory requirements, and scientific research. ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Specialty ... audit and been admitted to BPA Worldwide as ... Worldwide will track audience data for Specialty Pharmacy ... , “By becoming a member of BPA ... to providing our clients with the most reliable, ...
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... Sept. 10 Signalife, Inc. (Amex:,SGN) announced that the company,s ... stock to be effected in the form of a,reverse stock ... on September,19, 2008, which will be the record date and ... time of such reverse stock split, all,outstanding shares of Signalife ...
... 10 , - Abstracts 185 and 1112, ... announced results from,two randomized clinical studies presented at ... 44th Annual Meeting demonstrating that the,"basal plus" insulin ... daily (basal insulin) and APIDRA(R) once daily,(prandial insulin) ...
... Sept. 10 Abeome Corporation, a,Georgia-based biotech company, ... (SAB) to collaborate on the development of,Abeome,s ovarian ... therapeutic,and diagnostic projects for the company., The ... Meagher, PhD, Chief,Scientific Officer for Abeome, Distinguished Research ...
Cached Biology Technology:Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 3Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 4Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 5Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 6Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4Abeome Forms First Class Scientific Advisory Board 2
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... 2, 2013  Fingerprint Cards, swipe sensor ... well-renowned Asian OEM customer for an additional smartphone scheduled to be launched ... Fingerprint Cards (FPC) has earlier announced multiple mobile and tablet DWs ... Korea, with the first phones in Japan and ...
... is a bacterium that establishes a life-long stomach infection in ... or stomach cancer. New research, presented at this week,s Society ... of how these bacteria can manipulate the human immune system ... Researchers from the University of Nottingham have shown that ...
... the world have watched as strain after strain of the ... Over the last few decades researchers have used ... individual mutations that allow TB to withstand many of the ... markers serve as clues for new drug development and as ...
Cached Biology News:FPC Awarded new Smartphone DW From Existing Prominent Asian OEM Customer for Launch With Leading US Operator 2Stomach bacteria switch off human immune defences to cause disease 2Researchers untangle genetics of drug resistant TB 2Researchers untangle genetics of drug resistant TB 3Researchers untangle genetics of drug resistant TB 4
Human ICAT Affinity Purified Polyclonal Ab...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: